Emma Wade

Dr. Emma Wade

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EWEmma Wade
Emma Wade
PDPhilip B. Daniel
Philip B. Daniel
ZJZandra A. Jenkins
Zandra A. Jenkins
AMAideen McInerney-Leo
Aideen McInerney-Leo
PLPaul Leo
Paul Leo
SRStephen Robertson
Stephen Robertson

27 February 2020 in Human Mutation
Verified
Journal Article
Open access
PDF file
EWEmma Wade
Emma Wade
BHBen Halliday
Ben Halliday
ZJZandra A. Jenkins
Zandra A. Jenkins
AOAdam C. O'NEill
Adam C. O'NEill
SRStephen Robertson
Stephen Robertson
The X‐linked filaminopathies represent a diverse group of clinical conditions, all caused by variants in the gene FLNA. FLNA encodes the widely expressed actin binding protein, filamin A that has multiple roles during embryonic development including cell migration, mechanical sensing, and cell signaling. In this review, we discuss the 10 distinct X‐linked filaminopathy conditions that between them affect almost all organ systems, including the brain, skeleton, heart, and skin, highlighting the critical role of this protein in human development. We review each of the phenotypes and discuss their pathogenesis, where known. Assigning pathogenicity to variants in FLNA can prove difficult, especially for missense variants and small indels, in‐part because of the X‐linked nature of the phenotypes, the overlap of phenotypic features between conditions, and poor understanding of the function of certain protein domains. We outline here approaches to characterize phenotypes, highlight hotspot regions within FLNA commonly mutated in these conditions, and approaches to resolving some variants of uncertain significance.

1 June 2013 in Developmental Biology
Verified
Journal Article
Closed access
JMJason Meyers
Jason Meyers
JPJessica Planamento
Jessica Planamento
PEPierson Ebrom
Pierson Ebrom
NKNeil Krulewitz
Neil Krulewitz
EWEmma Wade
Emma Wade
MPMary Elizabeth (Betsy) Pownall
Mary Elizabeth (Betsy) Pownall

2 December 2019 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
SDSean G. W. Driver
Sean G. W. Driver
MJMeremaihi R. Jackson
Meremaihi R. Jackson
KRKonrad Richter
Konrad Richter
PTPaul Tomlinson
Paul Tomlinson
BBBen Brockway
Ben Brockway
EWEmma Wade
Emma Wade

12 May 2017 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
EWEmma Wade
Emma Wade
ZJZandra A. Jenkins
Zandra A. Jenkins
PDPhilip B. Daniel
Philip B. Daniel
TMTim Morgan
Tim Morgan
MAMarie C. Addor
Marie C. Addor
SRStephen Robertson
Stephen Robertson

22 November 2020 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
ABAlexander J. M. Blakes
Alexander J. M. Blakes
EGEmily Gaul
Emily Gaul
WLWayne Lam
Wayne Lam
NSNora Shannon
Nora Shannon
KKKaren M. Knapp
Karen M. Knapp
ADAndrew Douglas
Andrew Douglas
ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, germline missense variants in ABL1 have been found to cause an autosomal dominant developmental syndrome with congenital heart disease, skeletal malformations and characteristic facies. Here, we describe a series of six new unrelated individuals with heterozygous missense variants in ABL1 (including four novel variants) identified via whole exome sequencing. All the affected individuals in this series recapitulate the phenotype of the ABL1 developmental syndrome and additionally we affirm that hearing impairment is a common feature of the condition. Four of the variants cluster in the myristoyl-binding pocket of ABL1, a region critical for auto-inhibitory regulation of the kinase domain. Bio-informatic analysis of transcript-wide conservation and germline/somatic variation reveals that this pocket region is subject to high missense constraint and evolutionary conservation. Functional work to investigate ABL1 kinase activity in vitro by transient transfection of HEK293T cells with variant ABL1 plasmid constructs revealed increased phosphorylation of ABL1-specific substrates compared to wild-type. The increased tyrosine kinase activity was suppressed by imatinib treatment. This case series of six new patients with germline heterozygous ABL1 missense variants further delineates the phenotypic spectrum of this condition and recognises microcephaly as a common finding. Our analysis supports an ABL1 gain-of-function mechanism due to loss of auto-inhibition, and demonstrates the potential for pharmacological inhibition using imatinib.